NeoGenomics (NEO) – Management Comments
-
Guardant Health (GH) Sell-Off Makes Neogenomics (NEO) Deal Less Likely - Needham & Company
-
NeoGenomics (NEO) Reports Launch of Biomarker Assist KRAS SGT Program for Advanced or Metastatic NSCLC Patients
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to NEO Stock Lookup